Zimmermann Martina, Colciaghi Francesca, Cattabeni Flaminio, Di Luca Monica
Dept of Pharmacological Sciences, University of Milano, Italy.
Cell Mol Biol (Noisy-le-grand). 2002 Sep;48(6):613-23.
Ginkgo biloba is registered for the treatment of several diseases and disorders in Europe. In the United States, it is marketed as a dietary supplement; the French and the German agencies consider it to be effective for the treatment of several diseases, and the immense amount of clinical studies concerning Ginkgo biloba makes it worth revising the existing literature about this notable plant. A brief history of the common use of this drug will be followed by a short botanic characterization. The biochemical composition of the original drug, the leaf itself, will be described in detail together with a brief discussion of commercial extracts and the problem of studying Ginkgo biloba clinically to verify the safety and efficacy of its extracts in the treatment of disorders like Alzheimer's diseases. Aspects of molecular mechanisms modifying the efficacy of this drug will be outlined. Several agents like antioxidants, anti-inflammatory drugs, cholinergic agents, estrogens, or neurotrophic factors are in use for the treatment of this neurodegenerative disease, but none can prove fully convincing benefit. In this field, Ginkgo biloba appears as a useful and sensible supplementary medication to treat Alzheimer's disease, as it seems to be a synthesis of all the different profiles of action of the various, commonly used drugs but with less side effects.
银杏叶在欧洲被注册用于治疗多种疾病和病症。在美国,它作为一种膳食补充剂销售;法国和德国机构认为它对多种疾病的治疗有效,并且大量关于银杏叶的临床研究使得有必要对有关这种著名植物的现有文献进行修订。在简要介绍这种药物的常见用途历史之后,将进行简短的植物特征描述。将详细描述原始药物即叶片本身的生化成分,并简要讨论商业提取物以及临床研究银杏叶以验证其提取物在治疗诸如阿尔茨海默病等病症时的安全性和有效性的问题。将概述改变这种药物疗效的分子机制方面。几种药物如抗氧化剂、抗炎药、胆碱能药物、雌激素或神经营养因子正在用于治疗这种神经退行性疾病,但没有一种能充分证明其益处令人信服。在这个领域,银杏叶似乎是治疗阿尔茨海默病的一种有用且合理的辅助药物,因为它似乎综合了各种常用药物的不同作用模式,但副作用较少。